Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The Board approved the appointment of Frank Dixon Whitworth III as President of Satellogic Inc., effective September 7, 2026. While the disclosure includes compensatory details (base salary of $400,000, performance bonus target of $240,000, and RSU grants), the principal disclosed action is the appointment of a named executive officer to a senior leadership position. The compensation terms are ancillary to the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-09-08
Item 1.01
Circle Internet Group entered into a definitive Share Purchase Agreement on September 4, 2026, to acquire Tazapay Pte. Ltd., a Singapore-based cross-border payments platform, for approximately $400 million in Circle Common Stock. The acquisition brings $25+ billion in annualized payment volume, 60+ banking and fintech partners, and 100+ payout markets into Circle's ecosystem, with expected closing in 2027.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-08
Item 5.02
Todd Sisitsky's departure from his dual roles as President and Board member of TPG Inc., effective immediately as of September 6, 2026, constitutes a material executive departure. The disclosure centers on a named officer leaving his positions rather than a replacement appointment or compensation arrangement, making exec_departure the primary event type.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
The Board of Directors elected Michael J. Katz as a Class II director effective September 3, 2026, to serve until the 2027 annual meeting. This is a clear director appointment with detailed disclosure of his qualifications, including his extensive leadership experience at T-Mobile and recognition as one of Forbes' 50 most influential CMOs. Director appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-09-08
Item 1.01
D-Wave entered into a definitive Other Transaction Agreement with the U.S. Department of Commerce under the CHIPS and Science Act for up to $100 million in funding for quantum computing R&D, coupled with issuance of 7,095,721 shares of common stock to the Department at $14.093 per share, representing a material capital transaction and strategic partnership with significant equity dilution.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-09-08
EX-99.1
The exhibit is a commercial update and cash distribution announcement by Himalaya Shipping Ltd. The primary disclosure is the Board's approval of a cash distribution of US$0.25 per share for August 2026, with specific record dates, ex-dates, and payment dates provided. This is a routine but material dividend distribution to shareholders, distinct from the operational metrics (TCE earnings) also included in the announcement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
The filing discloses an unregistered sale of equity securities (Item 3.02) totaling approximately $38.7 million across three classes of common stock on September 1, 2026, exempt from registration under Section 4(a)(2). This is a material dilutive issuance of common stock that would affect investor assessment of ownership dilution and capital structure, particularly for a closed-end fund like Invesco Commercial Real Estate Finance Trust.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
North Haven Net REIT sold 3,254,849 common shares for approximately $68.1 million in an unregistered private offering under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance disclosed under Item 3.02, representing a material capital raise that would affect investor assessment of share dilution and the company's capitalization.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Inhibrx announced positive Phase 2 clinical trial results for INBRX-106 in head and neck squamous cell carcinoma, demonstrating a 48.3% response rate versus 26.5% for the control arm, with particularly strong results in HPV+ patients (80.0% vs 33.3%). The company plans to expand the trial and pursue an accelerated regulatory pathway.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-08
Item 5.02
Concentra Group Holdings Parent, Inc. announced a leadership succession involving the appointment of Tanner Newton as Executive Vice President and Chief Financial Officer effective November 1, 2026, concurrent with the promotion of Matthew DiCanio to President and CEO and Keith Newton to Executive Chairman.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 88%
filed 2026-09-08
Item 1.01
Everus Construction entered into a First Amendment to its Credit Agreement on September 1, 2026, refinancing existing term loans and revolving credit commitments while increasing total debt capacity by $325 million ($200M in term loans + $125M in revolving commitments). The proceeds are designated to refinance existing debt, fund the Epsilon Acquisition, and support general corporate purposes.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-08
Item 3.02
Ares Core Infrastructure Fund agreed to sell $767.0 million in aggregate of common shares across multiple classes (Class I, D, N, and S) at NAV, with the issuance exempted from Securities Act registration under Section 4(a)(2) and Regulation D Rule 506(b). This unregistered equity issuance materially dilutes existing shareholders and affects the Fund's capital structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-09-08
Item 5.02
Jack Weingart was appointed Chairperson of the T-POP Board effective September 6, 2026, in addition to his existing roles as CEO and board member. While Todd Sisitsky's concurrent resignation as Chairperson is disclosed, the principal action disclosed is Weingart's appointment to the chair role, making this an exec_appointment event. The appointment of a CEO to chair is material to investors' understanding of governance and leadership structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release discloses material progress on Mayfair Gold's exploration and development program at the Fenn-Gib Project, including completion of a 2026 summer geology program (mapping 95% of outcrops, 127 grab samples, 23 condemnation drill holes totalling 6,184 metres) and advancement of South Block targets toward drill-ready status for early 2027. The company is also building a comprehensive 3D geological and geochemical model to support mine development and exploration. While not a discrete M&A, financing, or governance event, this operational milestone—advancing a development-stage gold project toward construction (targeted 2028) and production (2030)—would materially affect a reasonable investor's assessment of the registrant's progress toward its stated development strategy and timeline.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-09-04
Synergy CHC Corp. filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on September 4, 2026, in the U.S. Bankruptcy Court for the District of Columbia (Case No. 26-465-ELG). This is disclosed under Item 1.03 and represents a terminal event materially threatening the registrant's continued existence. The filing is accompanied by related executive departures and appointment of a chief restructuring officer, but the bankruptcy filing is the primary material event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-04
Item 1.01
Zoomcar entered into securities purchase agreements for a private placement of Series A Convertible Preferred Stock and Warrants under Section 4(a)(2) and Regulation D Rule 506(c), with the Fifth Closing involving issuance of 80 Units (80 Preferred Shares convertible at $0.05/share and 80 Warrants exercisable at $0.0625/share). The offering termination date was extended from September 4, 2026 to September 20, 2026, representing a dilutive unregistered equity issuance typical of PIPE-like private placements to accredited investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-04
Item 5.02
Laird Superfood appointed Mark Johnson as Chief Financial Officer effective October 1, 2026. Johnson brings 25+ years of finance leadership experience in CPG companies and will serve as the company's principal financial officer and principal accounting officer reporting to the CEO, with a base salary of $375,000, bonus eligibility, and severance terms.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-09-04
Item 5.02
Mr. Gary Fan, Executive Vice President and Chief Operations Officer of Royal Business Bank, is departing effective September 30, 2026, following a mutual decision not to renew his employment agreement. While the disclosure also mentions severance terms (six months of base salary), the principal disclosed action is the departure of a named executive officer from a senior operational role. The materiality is supported by his C-suite position and the company's characterization of this as part of a "leadership transition plan."
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-04
The filing discloses unregistered sales of equity securities under Item 3.02, specifically the issuance of up to 11,445,080 shares of Common Stock (approximately 52% of pre-exchange outstanding shares) to Streeterville Capital in exchange for cancellation of $2.86 million in debt principal. The shares are issued in reliance on Section 3(a)(9) of the Securities Act without registration, representing a highly dilutive transaction that materially increases share count from 22.2 million to 33.6 million shares outstanding.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-09-04
Item 8.01
AMC Global Media settled a material breach-of-contract litigation with Robert Kirkman, Glen Mazzara, Gale Anne Hurd, and other producers for $120 million total ($85 million cash by September 18, 2026, plus $35 million by January 31, 2027), with dismissal with prejudice and mutual releases. The company took an $85 million charge in Q3 2026 related to this settlement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-03
Item 2.02
Campbell's issued a press release on September 3, 2026, announcing financial results for the quarter and full year ended August 2, 2026. The disclosure includes detailed quarterly and annual net sales, EBIT, and EPS figures, along with segment operating results and forward guidance for fiscal 2027. This is a standard earnings release attached as Exhibit 99.1 to Item 2.02, disclosing material financial results that would affect a reasonable investor's assessment of the company's performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-03
Item 2.02
Oxford Industries issued a press release on September 3, 2026, announcing financial results for the fiscal 2026 second quarter ended August 1, 2026. The disclosure includes consolidated net sales of $394 million, GAAP EPS of $3.25, adjusted EPS of $1.34, and revised full-year guidance lowering sales and EPS expectations due to softness in Lilly Pulitzer and macro-economic pressures. This is a standard quarterly earnings release with material financial results and forward guidance.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-09-03
Item 7.01
Tyson Foods disclosed a material revision to its fiscal 2026 financial outlook on September 3, 2026, reducing revenue growth guidance to 1.5%-2.0% and adjusted operating income to $1.85-$2.05 billion, driven by significant margin compression in the Beef segment due to cattle shortages and volatile prices. While this is a forward-looking guidance update rather than a historical earnings release, it represents a material financial event affecting investor expectations. The disclosure does not fit the specific "earnings_release" category (which typically covers actual quarterly/annual results) but is clearly a material financial disclosure warranting classification as financial_other.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-03
Item 5.02
Keith Stauffer was appointed as Vice President, Global Finance effective September 7, 2026, and Chief Financial Officer effective November 2, 2026. The appointment includes comprehensive compensation arrangements including base salary, equity awards, and a sign-on bonus.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-03
Item 2.02
The Toro Company announced its financial results for the three and nine month periods ended July 31, 2026, with a press release attached as Exhibit 99.1. The disclosure includes key metrics (net sales up 8.4% YoY to $1.23B, reported EPS up 50% YoY to $0.81, adjusted EPS up 7.3% YoY to $1.33), segment performance, and raised full-year guidance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-03
Item 2.02
Brady Corporation issued a press release on September 3, 2026 announcing its fiscal 2026 fourth quarter and full-year financial results, including record annual revenue and adjusted diluted EPS of $5.29 (15% increase), along with fiscal 2027 guidance projecting 23% adjusted diluted EPS growth.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-03
Item 8.01
Brady's Board approved an increase in the annual cash dividend on Class A Common Stock from $0.98 to $1.00 per share, with a quarterly dividend of $0.25 per share payable October 30, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-03
Item 5.07
This is a clear disclosure of shareholder vote results from NextEra Energy's special meeting held on September 3, 2026. The filing reports voting outcomes on three proposals: approval of share issuance to Dominion Energy shareholders in connection with a pending merger (99.47% for), authorization of additional common shares (99.02% for), and adjournment authority (92.33% for). The merger itself is material M&A activity, and shareholder approval of the merger consideration and related charter amendments are material governance events that would affect investor assessment of the transaction.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-09-03
Item 8.01
Brandywine Realty Trust entered into an Agreement of Sale on August 31, 2026 to sell a 441,000 square foot property at 3151 Market Street in Philadelphia for $240 million ($544 per square foot), with anticipated net proceeds of approximately $168 million after repaying the $57.3 million mortgage. This is a material asset disposition for a REIT, affecting capital structure and liquidity, but does not rise to the level of a change-of-control or merger (ma_activity), which typically involves acquisition or disposition of the entire company or a controlling interest. The sale is a significant financial event material to investors assessing the registrant's portfolio and cash position.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-03
Item 5.02
Christopher J. Hagedorn, Executive Vice President & Chief Strategy Officer, is departing his position effective September 30, 2026. The disclosure centers on the departure of a named executive officer from a senior leadership role, making this a clear exec_departure event. The departure of a C-suite executive responsible for strategy is material to investors' assessment of the company's leadership and direction.
View raw filing on EDGAR →
6-K
Terminal Other
confidence 95%
filed 2026-09-03
The 6-K furnishes the seventeenth report from joint provisional liquidators appointed by the Grand Court of the Cayman Islands on September 22, 2022, under Section 104(2) of the Companies Act. This is a liquidation proceeding — an existential event materially threatening the registrant's continued existence. While not a formal bankruptcy filing under U.S. law, the appointment of court-ordered liquidators and the ongoing liquidation process constitute a terminal event that does not fit the specific `bankruptcy_filing` category (which typically refers to Chapter 7/11 or analogous proceedings), making `terminal_other` the appropriate classification.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-09-03
ICICI Bank completed a purchase of 29,015,693 equity shares (approximately 2.00% of equity) in its subsidiary ICICI Prudential Life Insurance Company Limited through multiple tranches between July 22 and September 2, 2026, for approximately ₹14.70 billion, increasing its shareholding from approximately 50.8% to 52.8%. This represents a material acquisition activity involving a change in ownership stake in a significant subsidiary.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-09-03
EX-99.1
AC Immune SA held an Extraordinary General Meeting to propose the election of Tom Graney to the Board of Directors and the Audit and Finance Committee. Graney, who previously served on the board from 2016–2023, brings significant biotech and CFO/CEO experience to the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-09-03
Item 5.02
Halide Alagoz was appointed Chief Operating & Product Officer, effective November 29, 2026, with expanded responsibilities including AI strategy and architecture & design, following Bob Ranftl's retirement as Chief Operating Officer. This represents a significant change in the Company's operational leadership structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-03
Item 8.01
NVIDIA entered into a definitive agreement to acquire Hugging Face for approximately $11.9 billion plus up to $1.0 billion in equity-based retention, with closing expected in H1 2027. This is a material acquisition transaction disclosed under Item 8.01 (Other Events), representing a significant capital deployment and strategic business combination that would materially affect a reasonable investor's assessment of NVIDIA.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-03
Item 1.01
Medicus Pharma entered into a Co-Development and License Agreement with Pfizer on September 2, 2026, granting an exclusive, worldwide license to develop and commercialize CD228V, an early-stage antibody-drug conjugate. The transaction involves a $12.0 million upfront payment, $15.0 million deferred payment, potential milestone payments exceeding $1.0 billion, and royalties on net sales. This constitutes a material strategic transaction involving acquisition of intellectual property rights and a significant financial commitment that would materially affect a reasonable investor's assessment of the company's pipeline and financial obligations.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 90%
filed 2026-09-03
Item 5.02
Alaska Silver Corp. granted 375,000 stock options to non-executive directors at an exercise price of C$0.71 per share with a five-year term, in accordance with the Company's director compensation policy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-03
Item 2.02
eGain issued a press release on September 3, 2026 announcing financial results for its fiscal 2026 fourth quarter and full year ended June 30, 2026. The disclosure includes comprehensive financial highlights (revenue, gross margin, net income, EBITDA, cash position), forward guidance for Q1 and FY2027, and key business metrics. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-03
Item 2.02
Pro-Dex issued a press release on September 3, 2026, announcing financial results for its fourth fiscal quarter and full fiscal year ended June 30, 2026. The disclosure includes detailed quarterly and annual net sales ($20.4M and $77.5M respectively), gross profit, operating income, and net income ($2.9M and $13.7M respectively) with per-share metrics. This is a standard earnings release attached as Exhibit 99.1 and disclosed under Item 2.02, which is the designated Item for earnings announcements.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-03
Item 5.02
Jennifer Y. Ryu resigned as Executive Vice President and Chief Financial Officer, effective October 2, 2026. Jessica Block was appointed as interim CFO to assume the responsibilities of the departing financial officer.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-09-03
Item 1.01
The filing discloses closure of a stock repurchase agreement for 14.6 million common shares from the Propst Family Trust on August 28, 2026. While Item 1.01 typically covers M&A or material agreements, this is a share repurchase—a capital allocation and shareholder return event. The scale (14.6M shares) suggests materiality, but the event does not fit the specific categories of dividend_distribution (which typically covers declared/paid distributions) or ma_activity (which centers on acquisitions, dispositions, or control changes). This is best classified as a financial capital event outside the named taxonomy.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-09-03
EX-99.1
The announcement discloses the grant of 45,876 restricted share units (RSUs) to two independent non-executive directors—Ms. Xiaohong Chen (32,112 RSUs) and Mr. Hansong Zhu (13,764 RSUs)—on September 2, 2026, pursuant to the 2020 Share Incentive Plan. This is a compensatory arrangement for directors involving equity awards, which falls squarely within the exec_compensation category. The disclosure includes vesting conditions (one-year cliff vesting), clawback mechanisms, and explicit reference to the directors' remuneration packages, confirming this is a material compensation event affecting the registrant's governance and director incentive structure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-03
EX-99.1
This is a press release announcing Amber International's Q2 2026 unaudited financial results, with total revenue of US$13.9 million (up 38.8% QoQ), gross margin expansion to 79.5%, and a return to positive operating income and Adjusted EBITDA. The disclosure includes detailed financial metrics, business highlights, and management commentary on the company's strategic pivot to specialized AI agents. This is a material earnings announcement that would affect a reasonable investor's assessment of the registrant's financial performance and strategic direction.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Liquidia announced FDA Fast Track designation for YUTREPIA (treprostinil) inhalation powder for treatment of Raynaud's phenomenon associated with systemic sclerosis. This is a regulatory milestone that accelerates development and review timelines for a clinical-stage indication, representing material progress in the company's pipeline. While not a completed M&A transaction or earnings release, this operational/regulatory achievement would affect a reasonable investor's assessment of the company's development prospects and competitive position.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-03
EX-99.1
This is a press release announcing preliminary unaudited financial results for the six months ended June 30, 2026. The exhibit discloses revenue of $9.9 million (24.6% growth), gross profit of $8.6 million (32.0% increase), and a turnaround to net income of $13,499 from a net loss of $(11.4) million in the prior-year period. The release includes consolidated balance sheets and statements of operations, making it a discrete earnings announcement rather than a periodic financial report filing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-03
Item 7.01
AbbVie announced the completion of its acquisition of Apogee Therapeutics for approximately $10.9 billion ($135.11 per share in cash). This is a material acquisition disclosed under Item 7.01 (Regulation FD Disclosure) via press release. The filing explicitly states "AbbVie Inc. (the "Company") issued a press release announcing the completion of its acquisition of Apogee Therapeutics, Inc." The transaction materially expands AbbVie's immunology pipeline with late-stage assets (zumilokibart and APG273) and is expected to impact 2026-2027 earnings per share.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-03
EX-99.1
This exhibit announces a corporate rebranding from "Bit Origin Ltd" to "SANGRIX INC." approved by shareholder special resolution on August 21, 2026, with a corresponding ticker symbol change from BTOG to SGRX effective September 4, 2026. While primarily a governance/administrative matter (name and ticker change), the rebranding is material because it signals a strategic pivot toward AI computing infrastructure and reflects the company's evolving business direction, which would affect investor assessment of the registrant's strategic positioning and identity.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-03
The 6-K discloses the issuance and sale of $2.3 billion in aggregate principal amount of Senior Non-Preferred Fixed and Floating Rate Notes due 2029–2031, evidenced by pricing agreements and supplemental indentures dated September 3, 2026. This constitutes creation of new direct financial obligations and is material to investors assessing the registrant's capital structure and leverage.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-03
GeoPark announces a major strategic acquisition of the Bare Block in Venezuela through a Production Participation Contract (CPP) framework with PDVSA, structured as an exchange of 42.1 million GeoPark shares (at US$12.22/share, a 26% premium) to Grupo Gilinski, resulting in Grupo Gilinski becoming a controlling shareholder with ~56.3% ownership. This constitutes a material acquisition and change of control transaction that fundamentally transforms GeoPark's portfolio and ownership structure, with expected production increases to 75–85 kboepd by 2030 (2.7x current levels) and significant EBITDA accretion.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-03
Item 8.01
Milestone Pharmaceuticals announced China's NMPA approval of etripamil nasal spray for PSVT treatment, marking the first regulatory approval outside the United States. This is a material operational/regulatory milestone that triggers a $2.0 million payment and positions the company for up to $98 million in future milestone payments and royalties through its licensing partner Everest Medicines. While this is a significant product approval event, it does not fit neatly into the specific operational categories (workforce reduction, material contract, partnership) but represents a major regulatory and commercial milestone for the company's pipeline expansion.
View raw filing on EDGAR →